RU2015106909A - Антидиабетические трициклические соединения - Google Patents
Антидиабетические трициклические соединения Download PDFInfo
- Publication number
- RU2015106909A RU2015106909A RU2015106909A RU2015106909A RU2015106909A RU 2015106909 A RU2015106909 A RU 2015106909A RU 2015106909 A RU2015106909 A RU 2015106909A RU 2015106909 A RU2015106909 A RU 2015106909A RU 2015106909 A RU2015106909 A RU 2015106909A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- group
- unsubstituted
- substituted
- halogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 36
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 239000003472 antidiabetic agent Substances 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 claims abstract 39
- 229910052736 halogen Inorganic materials 0.000 claims abstract 37
- 150000002367 halogens Chemical class 0.000 claims abstract 37
- 150000003839 salts Chemical class 0.000 claims abstract 33
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 20
- 239000001257 hydrogen Substances 0.000 claims abstract 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 18
- 125000003118 aryl group Chemical group 0.000 claims abstract 10
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 10
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 10
- 150000001204 N-oxides Chemical class 0.000 claims abstract 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 7
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 7
- 239000001301 oxygen Substances 0.000 claims abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 3
- 125000000217 alkyl group Chemical group 0.000 claims 93
- 125000004093 cyano group Chemical group *C#N 0.000 claims 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 5
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 2
- 230000008484 agonism Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 claims 1
- 102000057234 Acyl transferases Human genes 0.000 claims 1
- 108700016155 Acyl transferases Proteins 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- 101001078593 Caenorhabditis elegans 3beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase 1 Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 claims 1
- 101710142060 Free fatty acid receptor 1 Proteins 0.000 claims 1
- 108091006027 G proteins Proteins 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- 102000030782 GTP binding Human genes 0.000 claims 1
- 108091000058 GTP-Binding Proteins 0.000 claims 1
- 229940122904 Glucagon receptor antagonist Drugs 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 101000618112 Homo sapiens Sperm-associated antigen 8 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 108010015181 PPAR delta Proteins 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 claims 1
- 102100040918 Pro-glucagon Human genes 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 claims 1
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 claims 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims 1
- 102100021913 Sperm-associated antigen 8 Human genes 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 230000003579 anti-obesity Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 229920000080 bile acid sequestrant Polymers 0.000 claims 1
- 229940096699 bile acid sequestrants Drugs 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 1
- 229960000815 ezetimibe Drugs 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 229940121380 ileal bile acid transporter inhibitor Drugs 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 229960004738 nicotinyl alcohol Drugs 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 239000002530 phenolic antioxidant Substances 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims 1
- 229960004034 sitagliptin Drugs 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000007201 aphasia Diseases 0.000 abstract 1
- 0 C[C@]([C@@]([C@@]1C2)[C@]1c(cn1)c2cc1OCCc1c(C)ccc(C(C(C=N)=C)=CC=C(*)COCCCC(C)(C)O)c1)O Chemical compound C[C@]([C@@]([C@@]1C2)[C@]1c(cn1)c2cc1OCCc1c(C)ccc(C(C(C=N)=C)=CC=C(*)COCCCC(C)(C)O)c1)O 0.000 description 2
- CJXBOBCVUOAOAS-XCRWMPKNSA-N CS(CCCOc(cc1)cc(C(F)(F)F)c1-c(cc1)cc(COC2=C[IH]C=C([C@@H]([C@H]3C4)[C@H]3C(O)=O)C4=C2)c1F)(=O)=O Chemical compound CS(CCCOc(cc1)cc(C(F)(F)F)c1-c(cc1)cc(COC2=C[IH]C=C([C@@H]([C@H]3C4)[C@H]3C(O)=O)C4=C2)c1F)(=O)=O CJXBOBCVUOAOAS-XCRWMPKNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1. Соединение структурной формулы I:или его фармацевтически приемлемая соль; гдеX выбран из группы, состоящей из:(1) кислорода и(2) NH;T выбран из группы, состоящей из: CH, N и N-оксида;U выбран из группы, состоящей из: CH, N и N-оксида;V выбран из группы, состоящей из: CH, N и N-оксида;при условии, что один или два из T, U и V обозначают N или N-оксид;A выбран из группы, состоящей из:(1) арила и(2) гетероарила,где A является незамещенным или замещен одним-пятью заместителями, выбранными из R;B выбран из группы, состоящей из:(1) арила,(2) арил-О-,(3) Cциклоалкила-,(4) Cциклоалкил-Cалкила-,(5) Cциклоалкил-Cалкил-O-,(6) Cциклогетероалкила-,(7) гетероарила,(8) гетероарил-О-,(9) арил-Cалкила- и(10) гетероарил-Cалкила-;где B является незамещенным или замещен одним-пятью заместителями, выбранными из R;Rвыбран из группы, состоящей из:(1) галогена,(2) -OR,(3) -CN,(4) -Cалкила и(5) -Cциклоалкила,где каждый -Cалкил и -Cциклоалкил является незамещенным или замещен одним-тремя заместителями, выбранными из R;Rвыбран из группы, состоящей из:(1) водорода,(2) -Cалкила и(3) -Cциклоалкила,где каждый -Cалкил и -Cциклоалкил является незамещенным или замещен одним-тремя заместителями, выбранными из R;Rвыбран из группы, состоящей из:(1) водорода,(2) галогена,(3) -OR,(4) -Cалкила,(5) -Cалкенила,(6) -Cалкинила и(7) -Cциклоалкила,где каждый Cалкил,Cалкенил,Cалкинил иCциклоалкил является незамещенным или замещен одним-тремя заместителями, выбранными из R;Rвыбран из группы, состоящей из:(1) водорода,(2) галогена,(3) -OR,(4) -Cалкила,(5) -Cалкенила,(6) -Cалкинила и(7) -Cциклоалкила,где каждый -Cалкил, -Cалкенил, -Cалкинил и -Cциклоалкил является незамещенным или замещен одним-тремя заместителями, выбранными из R;Rвыбран из группы, состоящей из:(1) водорода,(2) -Cалкила и(3) галогена;Rвыбран из группы, состоящей из:(1) водорода,(2) -Cалкила и(3) галогена, илиRи Rмогут вместе образовывать оксо;Rвыбран из группы,
Claims (31)
1. Соединение структурной формулы I:
или его фармацевтически приемлемая соль; где
X выбран из группы, состоящей из:
(1) кислорода и
(2) NH;
T выбран из группы, состоящей из: CH, N и N-оксида;
U выбран из группы, состоящей из: CH, N и N-оксида;
V выбран из группы, состоящей из: CH, N и N-оксида;
при условии, что один или два из T, U и V обозначают N или N-оксид;
A выбран из группы, состоящей из:
(1) арила и
(2) гетероарила,
где A является незамещенным или замещен одним-пятью заместителями, выбранными из Rа;
B выбран из группы, состоящей из:
(1) арила,
(2) арил-О-,
(3) C3-6циклоалкила-,
(4) C3-6циклоалкил-C1-10алкила-,
(5) C3-6циклоалкил-C1-10алкил-O-,
(6) C2-5циклогетероалкила-,
(7) гетероарила,
(8) гетероарил-О-,
(9) арил-C1-10алкила- и
(10) гетероарил-C1-10алкила-;
где B является незамещенным или замещен одним-пятью заместителями, выбранными из Rb;
R1 выбран из группы, состоящей из:
(1) галогена,
(2) -ORe,
(3) -CN,
(4) -C1-6алкила и
(5) -C3-6циклоалкила,
где каждый -C1-6алкил и -C3-6циклоалкил является незамещенным или замещен одним-тремя заместителями, выбранными из Ri;
R2 выбран из группы, состоящей из:
(1) водорода,
(2) -C1-6алкила и
(3) -C3-6циклоалкила,
где каждый -C1-6алкил и -C3-6циклоалкил является незамещенным или замещен одним-тремя заместителями, выбранными из Rj;
R3 выбран из группы, состоящей из:
(1) водорода,
(2) галогена,
(3) -ORe,
(4) -C1-6алкила,
(5) -C2-6алкенила,
(6) -C2-6алкинила и
(7) -C3-6циклоалкила,
где каждый C1-6алкил, C2-6алкенил, C2-6алкинил и C3-6циклоалкил является незамещенным или замещен одним-тремя заместителями, выбранными из RL;
R4 выбран из группы, состоящей из:
(1) водорода,
(2) галогена,
(3) -ORe,
(4) -C1-6алкила,
(5) -C2-6алкенила,
(6) -C2-6алкинила и
(7) -C3-6циклоалкила,
где каждый -C1-6алкил, -C2-6алкенил, -C2-6алкинил и -C3-6циклоалкил является незамещенным или замещен одним-тремя заместителями, выбранными из RL;
R5 выбран из группы, состоящей из:
(1) водорода,
(2) -C1-3алкила и
(3) галогена;
R6 выбран из группы, состоящей из:
(1) водорода,
(2) -C1-3алкила и
(3) галогена, или
R5 и R6 могут вместе образовывать оксо;
Ra выбран из группы, состоящей из:
(1) -C1-6алкила,
(2) галогена,
(3) -ORe,
(4) -NRcS(O)mRe,
(5) -S(O)mRe,
(6) -S(O)mNRcRd,
(7) -NRcRd,
(8) -C(O)Re,
(9) -OC(O)Re,
(10) -CO2Re,
(11) -CN,
(12) -C(O)NRcRd,
(13) -NRcC(O)Re,
(14) -NRcC(O)ORe,
(15) -NRcC(O)NRcRd,
(16) -CF3,
(17) -OCF3,
(18) -OCHF2,
(19) -C3-6циклоалкила и
(20) -C2-5циклогетероалкила;
Rb независимо выбран из группы, состоящей из:
(1) -C1-10алкила,
(2) -C2-10алкенила,
(3) галогена,
(4) -ОН,
(5) -OC1-10алкила,
(6) -OC2-10алкенила,
(7) -O(CH2)pOC1-10алкила,
(8) -O(CH2)pC3-6циклоалкила,
(9) -O(CH2)pC3-6циклоалкил-C1-10алкила-,
(10) -O(CH2)pC2-10циклогетероалкила,
(11) -O(CH2)pC2-5циклогетероалкил-C1-10алкила-,
(12) -О-арила,
(13) -О-гетероарила,
(14) -O-арил-C1-10алкила-,
(15) -O-гетероарил-C1-10алкила-,
(16) -NRcS(O)mRe,
(17) -S(O)mRe,
(18) -S(O)mNRcRd,
(19) -NRcRd,
(20) -C(O)Re,
(21) -OC(O)Re,
(22) -CO2Re,
(23) -CN,
(24) -C(O)NRcRd,
(25) -NRcC(O)Re,
(26) -NRcC(O)ORe,
(27) -NRcC(O)NRcRd,
(28) -O(CH2)pO-C3-6циклоалкила,
(29) -O(CH2)pO-C2-10циклогетероалкила,
(30) -CF3,
(31) -OCF3,
(32) -OCHF2,
(33) -(CH2)p-C3-6циклоалкила,
(34) -(CH2)p-C2-10циклогетероалкила,
(35) арила,
(36) гетероарила,
(37) арил-C1-10алкила- и
(38) гетероарил-C1-10алкила-,
где каждый Rb является незамещенным или замещен одним-пятью заместителями, выбранными из Rk;
Rc и Rd, каждый независимо, выбран из группы, состоящей из:
(1) водорода,
(2) C1-10алкила,
(3) C2-10алкенила,
(4) C3-6циклоалкила,
(5) C3-6циклоалкил-C1-10алкила-,
(6) циклогетероалкила,
(7) циклогетероалкил-C1-10алкила-,
(8) арила,
(9) гетероарила,
(10) арил-C1-10алкила- и
(11) гетероарил-C1-10алкила-, или
Rc и Rd вместе с атомом(ами), к которому(ым) они присоединены, образуют 4-7-членное циклогетероалкильное кольцо, содержащее 0-2 дополнительных гетероатома, независимо выбранных из кислорода, серы и N-Rg, и где каждый RC и Rd является незамещенным или замещен одним-тремя заместителями, независимо выбранными из Rf;
каждый Rе независимо выбран из группы, состоящей из:
(1) водорода,
(2) -C1-10алкила,
(3) -C2-10алкенила,
(4) -C3-6циклоалкила,
(5) -C3-6циклоалкил-C1-10алкила-,
(6) -C2-5циклогетероалкила,
(7) -C2-5циклогетероалкил-C1-10алкила-,
(8) арила,
(9) гетероарила,
(10) арил-C1-10алкила- и
(11) гетероарил-C1-10алкила-,
где каждый Rе является незамещенным или замещен одним-тремя заместителями, выбранными из Rh;
каждый Rf выбран из группы, состоящей из:
(1) галогена,
(2) C1-10алкила,
(3) -ОН,
(4) -O-C1-4алкила,
(5) -S(O)m-C1-4алкила,
(6) -CN,
(7) -CF3,
(8) -OCHF2 и
(9) -OCF3,
где каждый C1-10алкил является незамещенным или замещен одним-тремя заместителями, независимо выбранными из: -ОН, галогена, циано и -S(O)2CH3;
каждый Rg выбран из группы, состоящей из:
(1) водорода,
(2) -C(O)Re и
(3) -C1-10алкила,
где -C1-10алкил является незамещенным или замещен одним-пятью атомами фтора;
каждый Rh выбран из группы, состоящей из:
(1) галогена,
(2) C1-10алкила,
(3) -OH,
(4) -O-C1-4алкила,
(5) -S(O)m-C1-4алкила,
(6) -CN,
(7) -CF3,
(8) -OCHF2 и
(9) -OCF3,
где каждый C1-10алкил является незамещенным или замещен одним-тремя заместителями, независимо выбранными из: -OH, галогена, циано и -S(O)2CH3;
Ri независимо выбран из группы, состоящей из:
(1) -C1-6алкила,
(2) -ORe,
(3) -NRcS(O)mRe,
(4) галогена,
(5) -S(O)mRe,
(6) -S(O)mNRcRd,
(7) -NRcRd,
(8) -C(O)Re,
(9) -OC(O)Re,
(10) -CO2Re,
(11) -CN,
(12) -C(O)NRcRd,
(13) -NRcC(O)Re,
(14) NRcC(O)ORe,
(15) -NRcC(O)NRcRd,
(16) -CF3,
(17) -OCF3,
(18) -OCHF2,
(19) -C3-6циклоалкила и
(20) -C2-5циклогетероалкила;
Rj независимо выбран из группы, состоящей из:
(1) -C1-6алкила,
(2) -ORe,
(3) -NRcS(O)mRe,
(4) галогена,
(5) -S(O)mRe,
(6) -S(O)mNRcRd,
(7) -NRcRd,
(8) -C(O)Re,
(9) -OC(O)Re,
(10) -CO2Re,
(11) -CN,
(12) -C(O)NRcRd,
(13) -NRcC(O)Rе,
(14) -NRcC(O)ORe,
(15) -NRcC(O)NRcRd,
(16) -CF3,
(17) -OCF3,
(18) -OCHF2,
(19) -C3-6циклоалкила и
(20) -C2-5циклогетероалкила;
каждый Rk независимо выбран из группы, состоящей из:
(1) галогена,
(2) -C1-10алкила,
(3) -OH,
(4) оксо,
(5) галогена,
(6) -O-C1-4алкила,
(7) -SO2-C1-6алкила,
(8) -C1-6алкил-SO2C1-6алкила,
(9) -CN,
(10) -CF3,
(11) -OCHF2,
(12) -OCF3,
(13) -NH2,
(14) -NHSO2C1-6алкила,
(15) -NHCOC1-6алкила,
(16) =N(OCH3),
(17) -P(O)(ОН)2 и
(18) -P(O)(OC1-6алкил)2,
где каждый C1-10алкил является незамещенным или замещен одним-тремя заместителями, независимо выбранными из: -OH, -OC1-6алкила, галогена, циано и -S(O)2C1-6алкила;
RL выбран из группы, состоящей из:
(1) -C1-6алкила,
(2) галогена,
(3) -ORe,
(4) -NRcS(O)mRe,
(5) -S(O)mRe,
(6) -S(O)mNRcRd,
(7) -NRcRd,
(8) -C(O)Re,
(9) -OC(O)Re,
(10) -CO2Re,
(11) -CN,
(12) -C(O)NRcRd,
(13) -NRcC(O)Rе,
(14) -NRcC(O)ORe,
(15) -NRcC(O)NRcRd,
(16) -CF3,
(17) -OCF3,
(18) -OCHF2,
(19) -C3-6циклоалкила и
(20) -C2-5циклогетероалкила;
каждый n независимо выбран из: 0, 1, 2, 3 или 4;
каждый m независимо выбран из: 0, 1 или 2; и
каждый p независимо выбран из: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 или 10.
2. Соединение по п. 1, в котором n=1; или его фармацевтически приемлемая соль.
3. Соединение по п. 2, в котором X обозначает кислород; или его фармацевтически приемлемая соль.
4. Соединение по п. 3, в котором T обозначает CH, U обозначает N или N-оксид, и V обозначает CH; или его фармацевтически приемлемая соль.
5. Соединение по п. 3, в котором T обозначает CH, U обозначает N, и V обозначает CH; или его фармацевтически приемлемая соль.
6. Соединение по п. 5, в котором A выбран из группы, состоящей из: фенила и пиридина, где A является незамещенным или замещен одним-пятью заместителями, выбранными из Ra; или его фармацевтически приемлемая соль.
7. Соединение по п. 5, в котором A обозначает фенил, где фенил является незамещенным или замещен одним-пятью заместителями, выбранными из Ra; или его фармацевтически приемлемая соль.
8. Соединение по п. 7, в котором B выбран из группы, состоящей из: арила и гетероарила, где B является незамещенным или замещен одним-пятью заместителями, выбранными из Rb; или его фармацевтически приемлемая соль.
9. Соединение по п. 7, в котором B выбран из группы, состоящей из: фенила, пиридина, пиримидина, тиазола, бензимидазола, бензотиазола, бензоксазола и бензизоксазола, где B является незамещенным или замещен одним-пятью заместителями, выбранными из Rb; или его фармацевтически приемлемая соль.
10. Соединение по п. 7, в котором B выбран из группы, состоящей из: фенила и пиридина, где B является незамещенным или замещен одним-пятью заместителями, выбранными из Rb; или его фармацевтически приемлемая соль.
11. Соединение по п. 10, в котором R1, R2, R5 и R6 обозначают водород; или его фармацевтически приемлемая соль.
12. Соединение по п. 11, в котором R3 и R4 выбраны из группы, состоящей из: водорода, галогена и -C1-6алкила, где каждый C1-6алкил является незамещенным или замещен одним-тремя заместителями, выбранными из RL; или его фармацевтически приемлемая соль.
13. Соединение по п. 11, в котором R3 и R4 обозначают водород; или его фармацевтически приемлемая соль.
14. Соединение по п. 13, в котором Rа выбран из группы, состоящей из: -C1-6алкила, галогена и -CF3, или его фармацевтически приемлемая соль.
15. Соединение по п. 14, в котором Rb независимо выбран из группы, состоящей из:
(1) -C1-10алкила,
(2) галогена,
(3) -OH,
(4) -OC1-10алкила,
(5) -O(CH2)pOC1-10алкила,
(6) -O(CH2)pC3-6циклоалкила,
(7) -O(CH2)pC2-10циклогетероалкила,
(8) -O(CH2)pO-C3-6циклоалкила,
(9) -O(CH2)pO-C2-10циклогетероалкила,
(10) -CF3,
(11) -OCF3,
(12) -OCHF2,
(13) -(CH2)p-C2-10циклогетероалкила и
(14) -S(O)2C1-10алкила,
где каждый Rb является незамещенным или замещен одним-пятью заместителями, выбранными из Rk; или его фармацевтически приемлемая соль.
16. Соединение по п. 14, в котором Rb независимо выбран из группы, состоящей из:
(1) -C1-10алкила,
(2) галогена,
(3) -OH,
(4) -OC1-10алкила,
(5) -O(CH2)pC2-10циклогетероалкила,
(6) -CF3 и
(7) -(CH2)p-C2-10циклогетероалкила,
где каждый Rb является незамещенным или замещен одним-пятью заместителями, выбранными из Rk; или его фармацевтически приемлемая соль.
17. Соединение по п. 16, в котором каждый Rk независимо выбран из группы, состоящей из:
(1) -C1-10алкила,
(2) -O-C1-4алкила,
(3) -OH,
(4) галогена,
(5) -SO2-C1-6алкила,
(6) -C1-6алкил-SO2C1-6алкила,
(7) -CN,
(8) -NHSO2C1-6алкила,
(9) =N(OCH3) и
(10) -P(O)(OC1-6алкил)2,
где каждый C1-10алкил является незамещенным или замещен одним-тремя заместителями, независимо выбранными из: -OH, -OC1-6алкила, галогена, циано и -S(O)2C1-6алкила; или его фармацевтически приемлемая соль.
18. Соединение по п. 16, в котором каждый Rk независимо выбран из группы, состоящей из:
(1) -C1-10алкила,
(2) -OH,
(3) галогена,
(4) -SO2-C1-6алкила,
(5) -C1-6алкил-SO2C1-6алкила и
(6) -CN,
где каждый C1-10алкил является незамещенным или замещен одним-тремя заместителями, независимо выбранными из: -OH, -OC1-6алкила, галогена, циано и -S(O)2C1-6алкила; или его фармацевтически приемлемая соль.
20. Соединение по п. 1, в котором:
n=1;
X обозначает кислород;
T обозначает CH;
U обозначает N;
V обозначает CH;
A выбран из группы, состоящей из: арила и гетероарила, где A является незамещенным или замещен одним-пятью заместителями, выбранными из Ra;
B выбран из группы, состоящей из: арила и гетероарила, где B является незамещенным или замещен одним-пятью заместителями, выбранными из Rb;
R1, R2, R5 и R6 обозначают водород; и
R3 и R4 выбраны из группы, состоящей из: водорода, галогена и -C1-6алкила, где каждый C1-6алкил является незамещенным или замещен одним-тремя заместителями, выбранными из RL;
или его фармацевтически приемлемая соль.
21. Соединение по п. 1, в котором:
n=1;
X обозначает кислород;
T обозначает CH;
U обозначает N;
V обозначает CH;
A выбран из группы, состоящей из: фенила и пиридина, где A является незамещенным или замещен одним-пятью заместителями, выбранными из Ra;
B выбран из группы, состоящей из: фенила, пиридина, пиримидина, тиазола, бензимидазола, бензотиазола, бензоксазола и бензизоксазола, где B является незамещенным или замещен одним-пятью заместителями, выбранными из Rb;
R1, R2, R3, R4, R5 и R6 обозначают водород;
Ra выбран из группы, состоящей из: -C1-6алкила, галогена и -CF3;
Rb независимо выбран из группы, состоящей из:
(1) -C1-10алкила,
(2) галогена,
(3) -OH,
(4) -OC1-10алкила,
(5) -O(CH2)pOC1-10алкила,
(6) -O(CH2)pC3-6циклоалкила,
(7) -O(CH2)pC2-10циклогетероалкила,
(8) -O(CH2)pO-C3-6циклоалкила,
(9) -O(CH2)pO-C2-10циклогетероалкила,
(10) -CF3,
(11) -OCF3,
(12) -OCHF2,
(13) -(CH2)p-C2-10циклогетероалкила и
(14) -S(O)2C1-10алкила,
где каждый Rb является незамещенным или замещен одним-пятью заместителями, выбранными из Rk; и
каждый Rk независимо выбран из группы, состоящей из:
(1) -C1-10алкила,
(2) -O-C1-4алкила,
(3) -OH,
(4) галогена,
(5) -SO2-C1-6алкила,
(6) -C1-6алкил-SO2C1-6алкила,
(7) -CN,
(8) -NHSO2C1-6алкила,
(9) =N(OCH3) и
(10) -P(O)(OC1-6алкил)2,
где каждый C1-10алкил является незамещенным или замещен одним-тремя заместителями, независимо выбранными из: -OH, -OC1-6алкила, галогена, циано и -S(O)2C1-6алкила;
или его фармацевтически приемлемая соль.
22. Соединение по п. 1, в котором
n=1;
X обозначает кислород;
T обозначает CH;
U обозначает N;
V обозначает CH;
A обозначает фенил, где фенил является незамещенным или замещен одним-пятью заместителями, выбранными из Ra;
B выбран из группы, состоящей из: фенила и пиридина, где B является незамещенным или замещен одним-пятью заместителями, выбранными из Rb;
R1, R2, R3, R4, R5 и R6 обозначают водород;
Ra выбран из группы, состоящей из: -C1-6алкила, галогена и -CF3;
Rb независимо выбран из группы, состоящей из:
(1) -C1-10алкила,
(2) галогена,
(3) -OH,
(4) -OC1-10алкила,
(5) -O(CH2)pC2-10циклогетероалкила,
(6) -CF3 и
(7) -(CH2)p-C2-10циклогетероалкила,
где каждый Rb является незамещенным или замещен одним-пятью заместителями, выбранными из Rk; и
каждый Rk независимо выбран из группы, состоящей из:
(1) -C1-10алкила,
(2) -OH,
(3) галогена,
(4) -SO2-C1-6алкила,
(5) -C1-6алкил-SO2C1-6алкила и
(6) -CN,
где каждый C1-10алкил является незамещенным или замещен одним-тремя заместителями, независимо выбранными из: -OH, -OC1-6алкила, галогена, циано и -S(O)2C1-6алкила;
или его фармацевтически приемлемая соль.
24. Фармацевтическая композиция, содержащая соединение по п. 1 или его фармацевтически приемлемую соль и фармацевтически приемлемый носитель.
25. Применение соединения по п. 1 или его фармацевтически приемлемой соли, для получения лекарственного средства, пригодного для лечения у млекопитающего нарушения, состояния или заболевания, которое является чувствительным к агонизму связанного с G-белком рецептора 40.
26. Применение соединения по п. 1 или его фармацевтически приемлемой соли, для получения лекарственного средства для лечения диабета типа 2.
27. Соединение по п. 1 или его фармацевтически приемлемая соль, для применения в терапии.
28. Способ лечения или профилактики нарушения, состояния или заболевания, которое является чувствительным к агонизму связанного с G-белком рецептора 40 у пациента, включающей введение терапевтически эффективного количества соединения по п. 1 или его фармацевтически приемлемой соли.
29. Способ лечения сахарного диабета типа 2 у пациента, включающий введение пациенту терапевтически эффективного количества соединения по п. 1 или его фармацевтически приемлемой соли.
30. Фармацевтическая композиция, содержащая
(1) соединение по п. 1 или его фармацевтически приемлемую соль;
(2) одно или более соединений, выбранных из группы, состоящей из:
(a) агонистов и частичных агонистов PPAR гамма;
(b) бигуанидов;
(с) ингибиторов протеинтирозин-фосфатазы-1B (PTP-1B);
(d) ингибиторов дипептидил-пептидазы IV (DP-IV);
(e) инсулина или миметиков инсулина;
(f) сульфонилмочевины;
(g) ингибиторов α-глюкозидазы;
(h) средств, которые улучшают липидный профиль пациента, где указанные средства выбраны из группы, состоящей из (i) ингибиторов HMG-CoA редуктазы, (ii) секвестрантов желчных кислот, (iii) никотинилового спирта, никотиновой кислоты или ее соли, (iv) агонистов PPARα, (v) ингибиторов абсорбции холестерина, (vi) ингибиторов ацил CoA:холестерин ацилтрансферазы (ACAT), (vii) ингибиторов CETP и (viii) фенольных антиоксидантов;
(i) двойных агонистов PPARα/γ;
(j) агонистов PPARδ;
(k) соединений против ожирения;
(l) ингибиторов транспортера илеальных желчных кислот;
(m) противовоспалительных средств;
(n) антагонистов рецептора глюкагона;
(o) GLP-1;
(p) GIP-1;
(q) аналогов GLP-1;
(r) ингибиторов HSD-1;
(s) ингибиторов SGLT 1 и
(t) ингибиторов SGLT 2; и
(3) фармацевтически приемлемый носитель.
31. Фармацевтическая композиция, содержащая соединение по п. 1 или его фармацевтически приемлемую соль и соединение, выбранное из симвастатина, эзетимиба и ситаглиптина; и фармацевтически приемлемый носитель.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2012/079558 | 2012-08-02 | ||
PCT/CN2012/079558 WO2014019186A1 (en) | 2012-08-02 | 2012-08-02 | Antidiabetic tricyclic compounds |
US201261696572P | 2012-09-04 | 2012-09-04 | |
US61/696,572 | 2012-09-04 | ||
PCT/US2013/052961 WO2014022528A1 (en) | 2012-08-02 | 2013-07-31 | Antidiabetic tricyclic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2015106909A true RU2015106909A (ru) | 2016-09-27 |
Family
ID=48998703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015106909A RU2015106909A (ru) | 2012-08-02 | 2013-07-31 | Антидиабетические трициклические соединения |
Country Status (12)
Country | Link |
---|---|
US (2) | US9527875B2 (ru) |
EP (1) | EP2880028B1 (ru) |
JP (1) | JP2015525782A (ru) |
KR (1) | KR20150036245A (ru) |
AR (1) | AR091962A1 (ru) |
AU (1) | AU2013296470B2 (ru) |
BR (1) | BR112015002080A2 (ru) |
CA (1) | CA2880901A1 (ru) |
MX (1) | MX2015001500A (ru) |
RU (1) | RU2015106909A (ru) |
TW (1) | TW201408644A (ru) |
WO (1) | WO2014022528A1 (ru) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
CN107383009B (zh) | 2012-06-13 | 2020-06-09 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
SG11201508328PA (en) | 2013-04-19 | 2015-11-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10011609B2 (en) | 2013-11-14 | 2018-07-03 | Cadila Healthcare Limited | Heterocyclic compounds |
US10519115B2 (en) | 2013-11-15 | 2019-12-31 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2015089809A1 (en) * | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
CN107438607B (zh) | 2015-02-20 | 2021-02-05 | 因赛特公司 | 作为fgfr抑制剂的双环杂环 |
JP7050797B2 (ja) * | 2016-10-25 | 2022-04-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物および使用 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
EP3709995A4 (en) | 2017-11-16 | 2021-04-14 | Merck Sharp & Dohme Corp. | BICYCLIC ANTIDIABETIC COMPOUNDS |
CA3099116A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
AU2019262195B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
CN110568100B (zh) * | 2019-09-12 | 2022-05-31 | 江西金水宝制药有限公司 | 一种米格列奈钙r-异构体的检测方法 |
JP2022552324A (ja) | 2019-10-14 | 2022-12-15 | インサイト・コーポレイション | Fgfr阻害剤としての二環式複素環 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Fgfr阻害剤としての三環式ヘテロ環 |
Family Cites Families (474)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3914250A (en) | 1974-08-01 | 1975-10-21 | American Home Prod | 1,4-Diazepino{8 6,5,4-jk{9 carbazoles |
JPS608117B2 (ja) | 1977-02-08 | 1985-02-28 | 財団法人微生物化学研究会 | 新生理活性物質エステラスチンおよびその製造法 |
DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
ZA821577B (en) | 1981-04-06 | 1983-03-30 | Boots Co Plc | Therapeutic agents |
US4452813A (en) | 1981-05-22 | 1984-06-05 | Taiho Pharmaceutical Company Limited | Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative |
FR2523584B1 (fr) | 1982-03-17 | 1985-06-28 | Rhone Poulenc Agrochimie | Halogenures d'acides s-(tertioalcoyl) alcoylphosphonothioiques, leur preparation et leur utilisation |
JPS58193541A (ja) | 1982-05-07 | 1983-11-11 | Konishiroku Photo Ind Co Ltd | 熱現像画像記録材料 |
CA1258454A (en) | 1982-08-10 | 1989-08-15 | Leo Alig | Phenethanolamines |
JPH0245181B2 (ja) | 1983-03-16 | 1990-10-08 | Fuji Photo Film Co Ltd | Netsugenzokaraakankozairyo |
GB8313320D0 (en) | 1983-05-14 | 1983-06-22 | Ciba Geigy Ag | Coating compositions |
GB8313322D0 (en) | 1983-05-14 | 1983-06-22 | Ciba Geigy Ag | Heterocyclic-(cyclo)aliphatic carboxylic acids |
GB8313321D0 (en) | 1983-05-14 | 1983-06-22 | Ciba Geigy Ag | Preparation of mercaptan substituted carboxylic acids |
CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
IE61928B1 (en) | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
US5391571A (en) | 1989-11-15 | 1995-02-21 | American Home Products Corporation | Cholesterol ester hydrolase inhibitors |
US5112820A (en) | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
US5081122A (en) | 1990-03-05 | 1992-01-14 | Sterling Drug Inc. | Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof |
US4973587A (en) | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
US5013837A (en) | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US6472178B1 (en) | 1998-02-27 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
US5349056A (en) | 1992-10-09 | 1994-09-20 | Regeneron Pharmaceuticals | Modified ciliary neurotrophic factors |
US5451677A (en) | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
US5292736A (en) | 1993-02-26 | 1994-03-08 | Sterling Winthrop Inc. | Morpholinoalkylindenes as antiglaucoma agents |
JPH06298731A (ja) | 1993-04-13 | 1994-10-25 | Fuji Photo Film Co Ltd | 複素環化合物の製造方法 |
FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
US5705515A (en) | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
IL113410A (en) | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
AU2395095A (en) | 1994-04-29 | 1995-11-29 | G.D. Searle & Co. | Method of using (h+/k+) atpase inhibitors as antiviral agents |
BR9509610A (pt) | 1994-11-07 | 1997-10-28 | Pfizer | Ligandos específicos de neuropeptideo Y1 |
US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
CA2211656A1 (en) | 1995-01-31 | 1996-08-08 | Margret B. Basinski | Anti-obesity proteins |
US5605886A (en) | 1995-01-31 | 1997-02-25 | Eli Lilly And Company | Anti-obesity proteins |
US5554727A (en) | 1995-01-31 | 1996-09-10 | Eli Lilly And Company | Anti-obesity proteins |
WO1996023515A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
US5559208A (en) | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
US5831115A (en) | 1995-04-21 | 1998-11-03 | Abbott Laboratories | Inhibitors of squalene synthase and protein farnesyltransferase |
US20020006964A1 (en) | 1995-05-16 | 2002-01-17 | Young James W. | Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds |
US5739106A (en) | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
AU7074496A (en) | 1995-09-18 | 1997-04-09 | Ligand Pharmaceuticals Incorporated | Ppar gamma antagonists for treating obesity |
FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
US6482927B1 (en) | 1995-11-27 | 2002-11-19 | Millennium Pharmaceuticals, Inc. | Chimeric proteins comprising the extracellular domain of murine Ob receptor |
WO1997020821A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl derivatives |
WO1997020820A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl compounds |
WO1997020823A2 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | 2-amino quinazoline derivatives as npy receptor antagonists |
WO1997020822A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Quinazolin-2,4-diazirines as npy receptor antagonist |
WO1997019682A1 (en) | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
ATE236137T1 (de) | 1996-02-02 | 2003-04-15 | Merck & Co Inc | Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit |
WO1997028115A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Antidiabetic agents |
EP0904079B1 (en) | 1996-02-02 | 2004-03-24 | Merck & Co., Inc. | Antidiabetic agents |
WO1997027847A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
US6017919A (en) | 1996-02-06 | 2000-01-25 | Japan Tobacco Inc. | Compounds and pharmaceutical use thereof |
AU712057B2 (en) | 1996-06-07 | 1999-10-28 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity |
IT1288388B1 (it) | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
US6180653B1 (en) | 1996-12-16 | 2001-01-30 | Banyu Pharmaceutical Co., Ltd. | Aminopyrazole derivatives |
JPH10237049A (ja) | 1996-12-24 | 1998-09-08 | Nippon Chemiphar Co Ltd | ベンズイソキサゾ−ル誘導体 |
JP2001508799A (ja) | 1997-01-21 | 2001-07-03 | スミスクライン・ビーチャム・コーポレイション | 新規カンナビノイド受容体モジュレータ |
BR9807096A (pt) | 1997-01-28 | 2000-04-18 | Merck & Co Inc | Composto, processos para o tratamento do diabetes, da obesidade em um mamìfero, para reduzir nìveis de triglicerìdeos e nìveis de colesterol ou elevar nìveis de lipoproteìnas de alta densidade, para diminuir a motilidade do intestino, para reduzir inflamação neurogênica das vias aéreas e a depressão e para tratar distúrbios gastrintestinais, e, composições para o tratamento dos distúrbios acima e farmacêutica |
JP2001511147A (ja) | 1997-02-04 | 2001-08-07 | ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・アーカンソー | 殺菌・殺カビ性のカルボキサミド類 |
CZ300754B6 (cs) | 1997-02-21 | 2009-08-05 | Bayer Aktiengesellschaft | Arylsulfonamidy a jejich analogy, zpusob jejich výroby, meziprodukty pro jejich výrobu, farmaceutické prostredky tyto látky obsahující a jejich použití |
ATE253073T1 (de) | 1997-03-07 | 2003-11-15 | Metabasis Therapeutics Inc | Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase |
AU6691798A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
US6284748B1 (en) | 1997-03-07 | 2001-09-04 | Metabasis Therapeutics, Inc. | Purine inhibitors of fructose 1,6-bisphosphatase |
US5948777A (en) | 1997-03-18 | 1999-09-07 | Smithkline Beecham Corporation | Cannabinoid receptor agonists |
FR2761266B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
FR2761265B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates |
CA2288122C (en) | 1997-04-23 | 2006-09-26 | Banyu Pharmaceutical Co., Ltd. | Neuropeptide y receptor antagonist |
US6001836A (en) | 1997-05-28 | 1999-12-14 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: cyanoguanidine derivatives |
SE9702457D0 (sv) | 1997-06-26 | 1997-06-26 | Pharmacia & Upjohn Ab | Screening |
KR20010021696A (ko) | 1997-07-11 | 2001-03-15 | 미즈노 마사루 | 퀴놀린 화합물 및 그의 의약용도 |
WO1999019313A1 (en) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
CN1280574A (zh) | 1997-10-27 | 2001-01-17 | 雷迪研究基金会 | 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物 |
US6440961B1 (en) | 1997-10-27 | 2002-08-27 | Dr. Reddy's Research Foundation | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
JP2002501909A (ja) | 1998-01-29 | 2002-01-22 | ドクター・レディーズ・リサーチ・ファウンデーション | 新規なアルカン酸およびその医薬における使用、並びにその製造方法、およびそれを含有する薬学的組成物 |
US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
EP1068207A1 (en) | 1998-04-02 | 2001-01-17 | Neurogen Corporation | AMINOALKYL SUBSTITUTED 9H-PYRIDINO 2,3-b]INDOLE AND 9H-PYRIMIDINO 4,5-b]INDOLE DERIVATIVES |
CN1289475C (zh) | 1998-04-29 | 2006-12-13 | 奥索-麦克尼尔药品公司 | 在肥胖症和其它病症的治疗中用作神经肽yy5受体配体的n-取代的氨基1,2,3,4-四氢化萘 |
NZ504106A (en) | 1998-05-27 | 2003-02-28 | Dr | Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them |
US6329395B1 (en) | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
EP1085869A4 (en) | 1998-06-11 | 2001-10-04 | Merck & Co Inc | SPIRO PIPERID DERIVATIVES AS MELANOCORTIN RECEPTORAGONISTS |
KR100903531B1 (ko) | 1998-07-15 | 2009-06-23 | 데이진 가부시키가이샤 | 티오벤즈이미다졸 유도체 |
DE19837627A1 (de) | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
HN1998000027A (es) | 1998-08-19 | 1999-06-02 | Bayer Ip Gmbh | Arilsulfonamidas y analagos |
US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
SK286080B6 (sk) | 1998-09-09 | 2008-03-05 | Metabasis Therapeutics, Inc. | Heterocyklické aromatické zlúčeniny obsahujúce fosfonátovú skupinu, ich použitie a farmaceutická kompozícia obsahujúca uvedené zlúčeniny |
WO2000015826A2 (en) | 1998-09-10 | 2000-03-23 | Millennium Pharmaceuticals, Inc. | Leptin induced genes |
US6337332B1 (en) | 1998-09-17 | 2002-01-08 | Pfizer Inc. | Neuropeptide Y receptor antagonists |
DE19844547C2 (de) | 1998-09-29 | 2002-11-07 | Aventis Pharma Gmbh | Polycyclische Dihydrothiazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
PT1121111E (pt) | 1998-10-15 | 2010-05-17 | Imp Innovations Ltd | Compostos para o tratamento de perda de peso |
AU6325899A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
JP2002527516A (ja) | 1998-10-21 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | 新規化合物、それらの製造及び使用 |
JP2002527501A (ja) | 1998-10-21 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | 新規化合物、その製造及び利用 |
AU756797B2 (en) | 1998-11-10 | 2003-01-23 | Banyu Pharmaceutical Co., Ltd. | Spiro-indolines as Y5 receptor antagonists |
US6344481B1 (en) | 1999-03-01 | 2002-02-05 | Pfizer Inc. | Thyromimetic antiobesity agents |
EP1178789B1 (en) | 1999-03-19 | 2008-07-16 | Abbott GmbH & Co. KG | Method of treating eating disorders |
FR2792314B1 (fr) | 1999-04-15 | 2001-06-01 | Adir | Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP2002543067A (ja) | 1999-04-22 | 2002-12-17 | シナプティック・ファーマスーティカル・コーポレーション | 選択的なnpy(y5)のアンタゴニスト |
US6340683B1 (en) | 1999-04-22 | 2002-01-22 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (triazines) |
EP1177172A1 (en) | 1999-05-05 | 2002-02-06 | Ortho-McNeil Pharmaceutical, Inc. | 3a,4,5,9b-TETRAHYDRO-1H-BENZ e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS |
EP1177188B1 (en) | 1999-05-12 | 2005-10-12 | Ortho-McNeil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
JP2003505435A (ja) | 1999-06-04 | 2003-02-12 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−4受容体ゴニストとしての置換ピペリジン |
JP2003503486A (ja) | 1999-06-30 | 2003-01-28 | シナプティック・ファーマスーティカル・コーポレーション | 選択的npy(y5)アンタゴニスト |
IL147308A0 (en) | 1999-06-30 | 2002-08-14 | Tularik Inc | Compounds for the modulation of pparγ activity and pharmaceutical compositions containing the same |
AU6000900A (en) | 1999-07-23 | 2001-02-13 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
US6380224B1 (en) | 1999-07-28 | 2002-04-30 | Ortho-Mcneil Pharmaceutical, Inc. | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
JP2003528810A (ja) | 1999-08-04 | 2003-09-30 | ミレニアム ファーマスーティカルズ インク | メラノコルチン−4受容体結合化合物及びその使用方法 |
TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
EP1219294A4 (en) | 1999-09-20 | 2005-01-26 | ANTAGONISTS OF THE MELANIN CONCENTRATING HORMON | |
HUP0202678A3 (en) | 1999-09-30 | 2004-06-28 | Pfizer | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines, pharmaceutical compositions containing them and their use |
EA200200424A1 (ru) | 1999-09-30 | 2002-12-26 | Ньюроджен Корпорейшн | Некоторые гетероциклы, замещенные алкилендиамином |
CN1377355A (zh) | 1999-09-30 | 2002-10-30 | 纽罗杰有限公司 | 氨基取代的吡唑并[1,5-a]-1,5-嘧啶和吡唑并[1,5-a]-1,3,5-三嗪 |
TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
WO2001025192A1 (en) | 1999-10-06 | 2001-04-12 | Melacure Therapeutics Ab | Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase |
EE200200191A (et) | 1999-10-13 | 2003-06-16 | Pfizer Products Inc. | Monoamiini taasomastamise inhibiitoritena kasulikud biarüüleetri derivaadid |
DE19949319A1 (de) | 1999-10-13 | 2001-06-13 | Ruetgers Vft Ag | Verfahren zur Herstellung von Arylalkylethern |
WO2001032638A1 (de) | 1999-11-05 | 2001-05-10 | Aventis Pharma Deutschland Gmbh | Indeno-, naphtho- und benzocyclohepta-dihydrothiazol derivate, deren herstellung und deren verwendung als anorektische arzneimittel |
WO2001044201A1 (en) | 1999-12-16 | 2001-06-21 | Schering Corporation | Substituted imidazole neuropeptide y y5 receptor antagonists |
EP1167360A1 (en) | 2000-01-17 | 2002-01-02 | Teijin Limited | Human chymase inhibitors |
SI1249450T1 (sl) | 2000-01-17 | 2008-04-30 | Teijin Pharma Ltd | Derivati benzimidola kot inhibitorji humane kimaze |
CA2396307A1 (en) | 2000-01-18 | 2001-07-26 | Merck & Co., Inc. | Cyclic peptides as potent and selective melanocortin-4 receptor antagonists |
AU2001228325A1 (en) | 2000-02-01 | 2001-08-14 | Novo-Nordisk A/S | Use of compounds for the regulation of food intake |
EP1254115A2 (en) | 2000-02-11 | 2002-11-06 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
JP2001226269A (ja) | 2000-02-18 | 2001-08-21 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
AU2001234128B2 (en) | 2000-02-22 | 2004-11-11 | Banyu Pharmaceutical Co., Ltd. | Novel imidazoline compounds |
GB0004003D0 (en) | 2000-02-22 | 2000-04-12 | Knoll Ag | Therapeutic agents |
ATE283265T1 (de) | 2000-02-23 | 2004-12-15 | Aventis Pharma Gmbh | 8,8a-dihydro-indeno (1,2-d)thiazol-derivate, die in 8a-stellung substituiert sind, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel z.b. als anorektika |
US6531478B2 (en) | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
AU4413601A (en) | 2000-02-26 | 2001-09-03 | Aventis Pharma Gmbh | 8,8a-dihydro-indeno(1,2-d)thiazole derivatives with a sulphonamido or sulphono substituent in the 2 position, a method for production thereof and use thereof as a medicament |
FR2805810B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
FR2805817B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
FR2805818B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
EP1132389A1 (en) | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
BRPI0109200B8 (pt) | 2000-03-14 | 2021-05-25 | Actelion Pharmaceuticals Ltd | compostos e composições farmacêuticas |
WO2001070337A1 (en) | 2000-03-23 | 2001-09-27 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
JP2004500401A (ja) | 2000-03-23 | 2004-01-08 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | Cb1−拮抗活性を有する4,5−ジヒドロ−1h−ピラゾール誘導体 |
AU4929601A (en) | 2000-03-23 | 2001-10-03 | Merck & Co Inc | Substituted piperidines as melanocortin receptor agonists |
US6600015B2 (en) | 2000-04-04 | 2003-07-29 | Hoffmann-La Roche Inc. | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity |
EP1142886A1 (en) | 2000-04-07 | 2001-10-10 | Aventis Pharma Deutschland GmbH | Percyquinnin, a process for its production and its use as a pharmaceutical |
JP2001354671A (ja) | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
EP1276710A1 (en) | 2000-04-17 | 2003-01-22 | Novo Nordisk A/S | New compounds, their preparation and use |
CA2407149C (en) | 2000-04-28 | 2010-10-12 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
GB0010757D0 (en) | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
GB0011013D0 (en) | 2000-05-09 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
US6444675B2 (en) | 2000-05-10 | 2002-09-03 | Bristol-Myers Squibb Company | 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists |
US6432960B2 (en) | 2000-05-10 | 2002-08-13 | Bristol-Myers Squibb Company | Squarate derivatives of dihydropyridine NPY antagonists |
US6479482B2 (en) | 2000-05-10 | 2002-11-12 | Bristol-Myers Squibb Company | Alkylamine derivatives of dihydropyridine NPY antagonists |
CA2408486A1 (en) | 2000-05-11 | 2001-11-15 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
WO2001087335A2 (en) | 2000-05-17 | 2001-11-22 | Eli Lilly And Company | Method for selectively inhibiting ghrelin action |
US6391881B2 (en) | 2000-05-19 | 2002-05-21 | Bristol-Myers Squibb Company | Thiourea derivatives of dihydropyridine NPY antagonists |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
WO2001091752A1 (en) | 2000-05-30 | 2001-12-06 | Merck & Co., Inc. | Melanocortin receptor agonists |
US6645987B2 (en) | 2000-06-15 | 2003-11-11 | Schering Corporation | Nor-seco himbacine derivatives useful as thrombin receptor antagonists |
PT1289955E (pt) | 2000-06-16 | 2005-08-31 | Smithkline Beecham Plc | Piperidinas para utilizacao como antagonistas dos receptores da orexina |
WO2002006245A1 (en) | 2000-07-05 | 2002-01-24 | Synaptic Pharmarceutical Corporation | Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
JP2004516239A (ja) | 2000-07-06 | 2004-06-03 | ニューロジェン コーポレイション | メラニン凝集ホルモン受容体リガンド |
GB0019357D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
WO2002008250A2 (en) | 2000-07-24 | 2002-01-31 | Ardana Bioscience Limited | Ghrelin antagonists |
WO2002010169A1 (en) | 2000-07-31 | 2002-02-07 | F. Hoffmann-La Roche Ag | Piperazine derivatives |
US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
GB0019359D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
NZ524618A (en) | 2000-08-10 | 2004-08-27 | Mitsubishi Pharma Corp | Proline derivatives and use thereof as drugs |
AU2001277723A1 (en) | 2000-08-11 | 2002-02-25 | Nippon Chemiphar Co., Ltd. | Ppardelta activators |
US20020042400A1 (en) | 2000-08-17 | 2002-04-11 | Yajing Rong | Novel alicyclic imidazoles as H3 agents |
JP2004506685A (ja) | 2000-08-21 | 2004-03-04 | グリアテツク・インコーポレイテツド | 食欲の制御と肥満の治療のためのヒスタミンh3受容体逆アゴニストの使用 |
US6680340B2 (en) | 2000-08-21 | 2004-01-20 | Merck & Co., Inc. | Anti-hypercholesterolemic drug combination |
AU2001288285B2 (en) | 2000-08-23 | 2005-09-29 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
US20020037829A1 (en) | 2000-08-23 | 2002-03-28 | Aronson Peter S. | Use of DPPIV inhibitors as diuretic and anti-hypertensive agents |
US6900226B2 (en) | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
JP2004509108A (ja) | 2000-09-14 | 2004-03-25 | シェーリング コーポレイション | 置換尿素神経ペプチドyy5受容体アンタゴニスト |
WO2002026707A1 (en) | 2000-09-26 | 2002-04-04 | Biovitrum Ab | Novel compounds |
AU2001292480A1 (en) | 2000-09-26 | 2002-04-08 | Biovitrum Ab | Novel pyridazine compounds for the treatment of diabetes |
SK4182003A3 (en) | 2000-10-13 | 2004-01-08 | Lilly Co Eli | Substituted dipeptides as growth hormone secretagogues |
AR038762A1 (es) | 2000-10-16 | 2005-01-26 | Hoffmann La Roche | Derivados de indolina, un proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion y el uso de dichos derivados para la fabricacion de un medicamento |
SK4612003A3 (en) | 2000-10-20 | 2004-06-08 | Pfizer Prod Inc | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
WO2002036596A2 (en) | 2000-11-03 | 2002-05-10 | Wyeth | CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES |
WO2002038544A2 (en) | 2000-11-10 | 2002-05-16 | Eli Lilly And Company | 3-substituted oxindole beta 3 agonists |
EP1342717A4 (en) | 2000-11-15 | 2005-02-16 | Banyu Pharma Co Ltd | benzimidazole derivatives |
PL361690A1 (en) | 2000-11-20 | 2004-10-04 | Biovitrum Ab | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor |
EP1337518B1 (en) | 2000-11-20 | 2009-06-17 | Biovitrum AB (publ) | Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor |
ATE286897T1 (de) | 2000-11-28 | 2005-01-15 | Smithkline Beecham Plc | Morpholinderivate als antagonisten an orexinrezeptoren |
AU2002224139A1 (en) | 2000-12-05 | 2002-06-18 | Nippon Chemiphar Co. Ltd. | Ppar (peroxisome proliferator activated receptor) activators |
AU2002224138A1 (en) | 2000-12-05 | 2002-06-18 | Nippon Chemiphar Co. Ltd. | Peroxisome proliferator activated receptor d activators |
ATE310004T1 (de) | 2000-12-12 | 2005-12-15 | Neurogen Corp | Spiro(isobenzofuran-1,4'-piperidin)-3-one und 3h- spiroisobenzofuran-1,4'-piperidine |
GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
WO2002049648A1 (en) | 2000-12-21 | 2002-06-27 | Schering Corporation | Heteroaryl urea neuropeptide y y5 receptor antagonists |
CA2432008A1 (en) | 2000-12-22 | 2002-07-04 | Astrazeneca Ab | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
JP4025200B2 (ja) | 2000-12-22 | 2007-12-19 | シェーリング コーポレイション | ピペリジンmchアンタゴニストおよび肥満の処置におけるそれらの使用 |
KR100539143B1 (ko) | 2000-12-27 | 2005-12-26 | 에프. 호프만-라 로슈 아게 | 인돌 유도체 및 그의 5-ht2b 및 5-ht2c 수용체리간드로서의 용도 |
WO2002051232A2 (en) | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
WO2002059095A1 (en) | 2001-01-23 | 2002-08-01 | Eli Lilly And Company | Melanocortin receptor agonists |
US7291619B2 (en) | 2001-01-23 | 2007-11-06 | Eli Lilly And Company | Melanocortin receptor agonists |
WO2002059107A1 (en) | 2001-01-23 | 2002-08-01 | Eli Lilly And Company | Substituted piperidines/piperazines as melanocortin receptor agonists |
SK10802003A3 (sk) | 2001-02-02 | 2004-05-04 | Takeda Chemical Industries, Ltd. | Kondenzovaná heterocyklická zlúčenina, jej použitie a jej farmaceutický prípravok |
EP1363914A1 (en) | 2001-02-05 | 2003-11-26 | Dr. Reddy's Laboratories Ltd. | Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents |
WO2002062766A2 (en) | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
US20020119958A1 (en) | 2001-02-13 | 2002-08-29 | Shinichiro Tojo | Therapeutic agent for hyperlipidemia |
JP4114480B2 (ja) | 2001-02-24 | 2008-07-09 | インターナショナル・ビジネス・マシーンズ・コーポレーション | グローバル割込みおよびバリア・ネットワーク |
US7015235B2 (en) | 2001-02-28 | 2006-03-21 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
ATE430565T1 (de) | 2001-02-28 | 2009-05-15 | Merck & Co Inc | Acylierte piperidinderivate als melanocortin-4- rezeptoragonisten |
KR20030076716A (ko) | 2001-02-28 | 2003-09-26 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 효능제로서 아실화 피페리딘 유도체 |
GB0105772D0 (en) | 2001-03-08 | 2001-04-25 | Sterix Ltd | Use |
US6900329B2 (en) | 2001-03-21 | 2005-05-31 | Schering Corporation | MCH antagonists and their use in the treatment of obesity |
JP4557492B2 (ja) | 2001-03-21 | 2010-10-06 | ファーマコペイア ドラッグ ディスカバリー, インコーポレイテッド | Mch調節活性を有するアリール化合物およびビアリール化合物 |
EP1373216B1 (en) | 2001-03-22 | 2004-12-15 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
JP4157381B2 (ja) | 2001-03-23 | 2008-10-01 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤応答性受容体の活性化剤 |
WO2002079162A1 (fr) | 2001-03-28 | 2002-10-10 | Eisai Co., Ltd. | Acides carboxyliques |
AU782148B2 (en) | 2001-03-29 | 2005-07-07 | Molecular Design International, Inc. | Beta3-adrenoreceptor agonists, agonist compositions and methods of making and using the same |
US7244861B2 (en) | 2001-03-30 | 2007-07-17 | Eisai Co., Ltd. | Benzene compound and salt thereof |
GB0108631D0 (en) | 2001-04-05 | 2001-05-30 | Melacure Therapeutics Ab | Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors |
US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
PE20021081A1 (es) | 2001-04-12 | 2002-12-18 | Pharmacopeia Drug Discovery | Aril y biaril piperidinas con actividad moduladora mch |
US20040192673A1 (en) | 2001-05-05 | 2004-09-30 | Pascale Gaillard | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
IL158463A0 (en) | 2001-05-05 | 2004-05-12 | Smithkline Beecham Plc | N-aroyl cyclic amines |
US7030150B2 (en) | 2001-05-11 | 2006-04-18 | Trimeris, Inc. | Benzimidazole compounds and antiviral uses thereof |
FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AU2002338896B2 (en) | 2001-05-21 | 2006-04-27 | F.Hoffman-La Roche Ag | Quinoline derivatives as ligands for the neuropeptide Y receptor |
US6548538B2 (en) | 2001-05-22 | 2003-04-15 | Bayer Aktiengesellschaft | Propionic acid derivatives |
CN1703401A (zh) | 2001-05-22 | 2005-11-30 | 神经原公司 | 黑色素浓集激素受体的配体:取代的1-苄基-4-芳基哌嗪类似物 |
ES2257555T3 (es) | 2001-06-20 | 2006-08-01 | MERCK & CO., INC. | Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes. |
DE60224189T2 (de) | 2001-06-20 | 2008-12-11 | Merck & Co., Inc. | Dipeptidylpeptidase-hemmer zur behandlung von diabetes |
WO2003000685A1 (en) | 2001-06-20 | 2003-01-03 | Takeda Chemical Industries, Ltd. | 5-membered heterocycle derivatives |
US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
US7223791B2 (en) | 2001-06-26 | 2007-05-29 | Takeda Pharmaceutical Company Limited | Function regulator for retinoid relative receptor |
DE10150203A1 (de) | 2001-10-12 | 2003-04-17 | Probiodrug Ag | Peptidylketone als Inhibitoren der DPIV |
ZA200300833B (en) | 2001-06-27 | 2004-02-10 | Probiodrug Ag | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents. |
ES2339813T3 (es) | 2001-06-27 | 2010-05-25 | Glaxosmithkline Llc | Fluoropirrolidinas como inhibidores de dipeptidil peptidasas. |
US7196201B2 (en) | 2001-06-27 | 2007-03-27 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
ES2291477T3 (es) | 2001-06-27 | 2008-03-01 | Smithkline Beecham Corporation | Fluoropirrolidinas como inhibidores de dipeptidil peptidasa. |
ATE304545T1 (de) | 2001-06-29 | 2005-09-15 | Novo Nordisk As | Verfahren zur hemmung von tyrosinphosphatase 1b und/oder t-zellenprotein-tyrosinphosphatase und/oder anderen ptpasen mit einem asp-rest in position 48 |
US6688713B2 (en) | 2001-07-02 | 2004-02-10 | Mitsubishi Digital Electronics America, Inc. | Television base casting |
JP2005502624A (ja) | 2001-07-03 | 2005-01-27 | ノボ ノルディスク アクティーゼルスカブ | 糖尿病を治療するための、dpp−ivを阻害するプリン誘導体 |
HUP0401880A2 (hu) | 2001-07-05 | 2005-01-28 | Synaptic Pharmaceutical Corporation | Helyettesített anilin-piperidinek mint MCH-szelektív antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
JP3532537B2 (ja) | 2001-07-05 | 2004-05-31 | 株式会社テムコジャパン | 骨伝導ヘッドセット |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
ITMI20011483A1 (it) | 2001-07-11 | 2003-01-11 | Res & Innovation Soc Coop A R | Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi |
WO2003006604A2 (en) | 2001-07-12 | 2003-01-23 | Merck & Co., Inc. | Cyclic peptides as potent and selective melanocortin-4 receptor agonists |
WO2003007990A1 (fr) | 2001-07-18 | 2003-01-30 | Sumitomo Pharmaceuticals Company, Limited | Agoniste de la myosine |
JP4336196B2 (ja) | 2001-07-18 | 2009-09-30 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作動薬としての架橋ピペリジン誘導体 |
AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
MXPA04000707A (es) | 2001-07-26 | 2004-04-20 | Schering Corp | Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas. |
WO2003011267A1 (fr) | 2001-07-31 | 2003-02-13 | The Nisshin Oillio, Ltd. | Medicaments anti-obesite et ses substances |
WO2003014113A1 (en) | 2001-08-06 | 2003-02-20 | Glenmark Pharmaceuticals Limited | Novel benzopyran compounds and process for their preparation and use |
GB0119172D0 (en) | 2001-08-06 | 2001-09-26 | Melacure Therapeutics Ab | Phenyl pyrrole derivatives |
DE60231880D1 (de) | 2001-08-07 | 2009-05-20 | Banyu Pharma Co Ltd | Spiro isobenzofurane als neuropeptid y rezeptor antagonisten |
US7335723B2 (en) | 2001-08-08 | 2008-02-26 | Merck & Co., Inc. | Melanin-concentrating hormone antagonists |
PT1424330E (pt) | 2001-08-10 | 2011-12-22 | Nippon Chemiphar Co | Activador do receptor ä responsivo a proliferadores peroxissomais |
WO2003016307A1 (en) | 2001-08-14 | 2003-02-27 | Eli Lilly And Company | β3 ADRENERGIC AGONISTS |
DE60211199T2 (de) | 2001-08-14 | 2007-02-01 | Eli Lilly And Co., Indianapolis | 3-substituierte oxindol-beta-3-agonisten |
DE10139416A1 (de) | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
JPWO2003016265A1 (ja) | 2001-08-17 | 2004-12-02 | エーザイ株式会社 | 環状化合物およびpparアゴニスト |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
US20030092041A1 (en) | 2001-08-23 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Novel use for muscarinic receptor M5 in the diagnosis and treatment of metabolic disorders |
JP4173098B2 (ja) | 2001-08-24 | 2008-10-29 | 帝人株式会社 | キマーゼ阻害剤及びace阻害剤を有効成分として含有する薬剤 |
CA2457922A1 (en) | 2001-08-31 | 2003-03-13 | University Of Connecticut | Novel pyrazole analogs acting on cannabinoid receptors |
GB0121941D0 (en) | 2001-09-11 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
US6915444B2 (en) | 2001-09-12 | 2005-07-05 | Rockwell Automation Technologies, Inc. | Network independent safety protocol for industrial controller using data manipulation techniques |
EP1426370A4 (en) | 2001-09-13 | 2009-12-23 | Nisshin Pharma Inc | PROPANOLAMINE DERIVATIVE WITH 1,4-BENZODIOXANE CORE |
JP2005508907A (ja) | 2001-09-14 | 2005-04-07 | ノボ ノルディスク アクティーゼルスカブ | ヒスタミンh3受容体に選択的に結合する置換されたピペリジン |
KR20040033048A (ko) | 2001-09-14 | 2004-04-17 | 미츠비시 웰파마 가부시키가이샤 | 티아졸리딘 유도체 및 이의 약학적 용도 |
DE60237528D1 (de) | 2001-09-14 | 2010-10-14 | High Point Pharmaceuticals Llc | Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative |
MXPA04001785A (es) | 2001-09-14 | 2004-07-08 | Bayer Ag | Benzofurano y derivados de dihidrobenzofurano utiles como agonistas de beta-3 adrenoreceptores. |
KR20040063897A (ko) | 2001-09-14 | 2004-07-14 | 툴라릭, 인코포레이티드 | 링크된 바이아릴 화합물 |
WO2003024965A2 (en) | 2001-09-19 | 2003-03-27 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
WO2003024447A1 (en) | 2001-09-20 | 2003-03-27 | Smithkline Beecham Corporation | Inhibitors of glycogen synthase kinase-3 |
TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
SI1429761T1 (sl) | 2001-09-21 | 2007-02-28 | Solvay Pharm Bv | Novi 4,5-dihidro-1h-pirazolni derivati s cb1-antagonisticno aktivnostjo |
HUP0402113A3 (en) | 2001-09-21 | 2012-05-29 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof |
US6509367B1 (en) | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
EP1432708B1 (en) | 2001-09-24 | 2005-11-30 | Bayer Pharmaceuticals Corporation | Preparation and use of 1,5,6,7-tetrahydropyrrolo 3,2-c]pyridine derivatives for treatment of obesity |
PE20030547A1 (es) | 2001-09-24 | 2003-08-18 | Bayer Corp | Derivados de imidazol para el tratamiento de la obesidad |
CN100350968C (zh) | 2001-09-24 | 2007-11-28 | 皇家创新有限公司 | 饮食行为的改进 |
WO2003026576A2 (en) | 2001-09-24 | 2003-04-03 | Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College | Induction of brown adipocytes by transcription factor nfe2l2 |
CA2461144A1 (en) | 2001-09-24 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Preparation and use of pyrrole derivatives for treating obesity |
US6677352B1 (en) | 2001-09-26 | 2004-01-13 | Yamin Wang | 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders |
US6787558B2 (en) | 2001-09-28 | 2004-09-07 | Hoffmann-La Roche Inc. | Quinoline derivatives |
EP1432693A2 (en) | 2001-10-01 | 2004-06-30 | Taisho Pharmaceutical Co. Ltd. | Mch receptor antagonists |
US7119110B2 (en) | 2001-10-05 | 2006-10-10 | Interhealth Nutraceuticals Incorporated | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
AU2002336433A1 (en) | 2001-10-08 | 2003-04-22 | Eli Lilly And Company | Tricyclic compounds useful for modulating lxr |
US20030158209A1 (en) | 2001-10-09 | 2003-08-21 | Neurocrine Biosciences Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
MXPA04002931A (es) | 2001-10-12 | 2005-04-11 | Bayer Pharmaceuticals Corp | Heterociclos que contienen nitrogeno de 5 miembros sustituidos con fenilo para el tratamiento de la obesidad. |
US6573396B2 (en) | 2001-10-12 | 2003-06-03 | Exxonmobil Chemical Patents Inc. | Co-production of dialkyl carbonates and diols with treatment of hydroxy alkyl carbonate |
DE60232739D1 (de) | 2001-10-12 | 2009-08-06 | Nippon Chemiphar Co | Aktivator des peroxisomproliferator-aktivierten rezeptors delta |
GB0124627D0 (en) | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
NZ532285A (en) | 2001-10-16 | 2005-11-25 | Dr | Novel beta-phenyl-alpha oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds |
BR0213253A (pt) | 2001-10-17 | 2004-10-26 | Novo Nordisk As | Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento de condições mediadas por receptores nucleares e de diabetes tipo i, diabetes tipo ii, dislipidemia, sìndrome x (incluindo a sìndrome metabólica, i.e. tolerância prejudicada à glicose, resistência á insulina, hipertrigliceridemia e/ou ou obesidade), doenças cardiovasculares (incluindo aterosclerose) ou hipercolesteremia |
DE10151390A1 (de) | 2001-10-18 | 2003-05-08 | Bayer Ag | Essigsäurederivate |
KR20040048995A (ko) | 2001-10-25 | 2004-06-10 | 다케다 야쿠힌 고교 가부시키가이샤 | 퀴놀린 화합물 |
US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
EP1452526A1 (en) | 2001-10-29 | 2004-09-01 | Japan Tobacco Inc. | Indole compound and medicinal use thereof |
US7342117B2 (en) | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
BR0213791A (pt) | 2001-11-01 | 2004-12-07 | Janssen Pharmaceutica Nv | Derivados de amida como inibidores de glicogênio sintase quinase 3-beta |
KR20040048920A (ko) | 2001-11-01 | 2004-06-10 | 얀센 파마슈티카 엔.브이. | 글리코겐 신타아제 키나제 3-베타 저해제(gsk저해제)로서의 헤테로아릴 아민 |
GB0126292D0 (en) | 2001-11-01 | 2002-01-02 | Smithkline Beecham Plc | Compounds |
KR20040053210A (ko) | 2001-11-02 | 2004-06-23 | 화이자 프로덕츠 인크. | Pde9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료 |
HN2002000317A (es) | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
US6673815B2 (en) | 2001-11-06 | 2004-01-06 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US7163952B2 (en) | 2001-12-03 | 2007-01-16 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
CZ2004747A3 (cs) | 2001-12-21 | 2004-11-10 | Novo Nordisk A/S | Deriváty amidů jako GK aktivátory |
AU2002360732A1 (en) | 2001-12-26 | 2003-07-24 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
US6727261B2 (en) | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
CN101050215A (zh) | 2001-12-28 | 2007-10-10 | 阿卡蒂亚药品公司 | 作为单胺受体调节剂的螺氮杂环化合物 |
CA2474702A1 (en) | 2002-01-30 | 2003-08-07 | Tularik Inc | Heterocyclic arylsulfonamidobenzylic compounds |
JP4415216B2 (ja) | 2002-02-01 | 2010-02-17 | 大日本住友製薬株式会社 | 2−フランカルボン酸ヒドラジド化合物及びそれを含有する医薬組成物 |
WO2003072100A1 (en) | 2002-02-25 | 2003-09-04 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
RU2293721C2 (ru) | 2002-02-28 | 2007-02-20 | Джапан Тобакко Инк. | Сложноэфирные соединения и их применение в медицине |
ATE486842T1 (de) | 2002-03-12 | 2010-11-15 | Merck Sharp & Dohme | Substituierte amide |
EP1500648A4 (en) | 2002-04-25 | 2005-12-21 | Sumitomo Pharma | NEW PIPERIDINE DERIVATIVES |
WO2003091213A1 (fr) | 2002-04-25 | 2003-11-06 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'amide ou sels de ces derives |
JP2005534632A (ja) | 2002-05-10 | 2005-11-17 | ニューロクライン バイオサイエンセズ, インコーポレイテッド | メラノコルチンレセプターリガンドとしての置換ピペラジン |
DE10222034A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Tetrahydroisochinolin-Derivate |
CA2487315A1 (en) | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
WO2004000869A1 (en) | 2002-06-19 | 2003-12-31 | Karo Bio Ab | Glucocorticoid receptor ligands for the treatment of metabolic disorders |
DE10229777A1 (de) | 2002-07-03 | 2004-01-29 | Bayer Ag | Indolin-Phenylsulfonamid-Derivate |
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
SE0202134D0 (sv) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Therapeutic agents |
AU2003236827A1 (en) | 2002-07-08 | 2004-01-23 | Coloplast A/S | Conduit device |
AU2003246657A1 (en) | 2002-07-09 | 2004-01-23 | Actelion Pharmaceuticals Ltd. | 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives |
WO2004007439A1 (ja) | 2002-07-10 | 2004-01-22 | Sumitomo Pharmaceuticals Co., Ltd. | ビアリール誘導体 |
AU2003250050A1 (en) | 2002-07-18 | 2004-02-09 | Basf Aktiengesellschaft | Nadh-dependent cytochrome b5 reductase as a target for herbicides |
DE10233817A1 (de) | 2002-07-25 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
AU2003254481A1 (en) | 2002-07-27 | 2004-02-16 | Astrazeneca Ab | Chemical compounds |
ES2301833T3 (es) | 2002-07-29 | 2008-07-01 | Hoffmann La Roche | Derivados de benzodioxol. |
DE10238860A1 (de) | 2002-08-24 | 2004-03-04 | Bayerische Motoren Werke Ag | Brennstoff-Zelle mit einer das Brenngas über der Elektroden-Oberfläche verteilenden perforierten Folie |
US6849761B2 (en) | 2002-09-05 | 2005-02-01 | Wyeth | Substituted naphthoic acid derivatives useful in the treatment of insulin resistance and hyperglycemia |
AU2003273300A1 (en) | 2002-09-06 | 2004-03-29 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
WO2004022551A1 (ja) | 2002-09-06 | 2004-03-18 | Takeda Pharmaceutical Company Limited | フランまたはチオフェン誘導体およびその医薬用途 |
US20040138258A1 (en) | 2002-09-18 | 2004-07-15 | Hanauske-Abel Hartmut M. | Inhibitors of 11beta-hydroxysteroid dehydrogenase and uses therefor |
ATE344261T1 (de) | 2002-09-18 | 2006-11-15 | Glaxo Group Ltd | Cyclische n-aroylamine als orexinrezeptorantagonisten |
US7045527B2 (en) | 2002-09-24 | 2006-05-16 | Amgen Inc. | Piperidine derivatives |
US20060183789A1 (en) | 2002-09-25 | 2006-08-17 | Lavanya Rajachandran | Methods for preventing and treating obesity in patients with mc4 receptor mutations |
CA2498089A1 (en) | 2002-10-03 | 2004-06-17 | Novartis Ag | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
EP1556349A1 (en) | 2002-10-11 | 2005-07-27 | Astrazeneca AB | 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors |
AU2003263475A1 (en) | 2002-10-11 | 2004-05-04 | Koninklijke Philips Electronics N.V. | A unit for and method of image conversion |
WO2004037859A1 (ja) | 2002-10-11 | 2004-05-06 | Sanwa Kagaku Kenkyusho Co., Ltd. | Glp-1誘導体及びその経粘膜吸収型製剤 |
MXPA05004434A (es) | 2002-10-24 | 2005-07-26 | Sterix Ltd | Inhibidores de 11-beta-hidroxi esteroide deshidrogenasa tipo 1 y tipo 2. |
US6852748B1 (en) | 2002-10-30 | 2005-02-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide |
WO2004041795A1 (en) | 2002-10-30 | 2004-05-21 | Guilford Pharmaceuticals Inc. | Novel inhibitors of dipeptidyl peptidase iv |
DE10250743A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225986D0 (en) | 2002-11-07 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
AU2003276458A1 (en) | 2002-11-07 | 2004-06-07 | Astrazeneca Ab | 2-oxo-ethanesulfonamide derivates |
WO2004041266A1 (ja) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
DE10251927A1 (de) | 2002-11-08 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
US20050143449A1 (en) | 2002-11-15 | 2005-06-30 | The Salk Institute For Biological Studies | Non-steroidal farnesoid X receptor modulators and methods for the use thereof |
AU2003274601A1 (en) | 2002-11-18 | 2004-06-15 | Pfizer Products Inc. | Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides |
GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
EP1572669A2 (en) | 2002-11-22 | 2005-09-14 | Novo Nordisk A/S | 2,5-diketopiperazines for the treatment of obesity |
AU2003295842A1 (en) | 2002-11-25 | 2004-06-18 | Gni Ltd. | Inferring gene regulatory networks from time-ordered gene expression data using differential equations |
GB0227813D0 (en) | 2002-11-29 | 2003-01-08 | Astrazeneca Ab | Chemical compounds |
UY28103A1 (es) | 2002-12-03 | 2004-06-30 | Boehringer Ingelheim Pharma | Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos |
ATE440827T1 (de) | 2002-12-04 | 2009-09-15 | Ore Pharmaceuticals Inc | Melanocortin-rezeptormodulatoren |
JP2006509801A (ja) | 2002-12-11 | 2006-03-23 | イーライ・リリー・アンド・カンパニー | 新規mch受容体アンタゴニスト |
JP2004196702A (ja) | 2002-12-18 | 2004-07-15 | Yamanouchi Pharmaceut Co Ltd | 新規なアミド誘導体又はその塩 |
WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
US20040209928A1 (en) | 2002-12-30 | 2004-10-21 | Ravi Kurukulasuriya | Glucagon receptor antagonists/inverse agonists |
WO2004063194A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Heteroaryl compounds |
US7576108B2 (en) | 2003-01-06 | 2009-08-18 | Eli Lilly And Company | Substituted arylcyclopropylacetamides as glucokinase activators |
DE10301788B4 (de) | 2003-01-20 | 2005-08-25 | Aventis Pharma Deutschland Gmbh | Pharmazeutische Verwendung von Pyrimido[5,4-e][1,2,4]triazin-5,7-dionen |
TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
WO2004067509A1 (ja) | 2003-01-31 | 2004-08-12 | Sanwa Kagaku Kenkyusho Co., Ltd. | ジペプチジルペプチダーゼivを阻害する化合物 |
US6759546B1 (en) | 2003-02-04 | 2004-07-06 | Allergan, Inc. | 3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity |
WO2004072041A1 (en) | 2003-02-12 | 2004-08-26 | Care X S.A. | Tetrahydroquinolines as agonists of liver- x receptors |
WO2004071454A2 (en) | 2003-02-13 | 2004-08-26 | Guilford Pharmaceuticals Inc. | Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv |
US20040167183A1 (en) | 2003-02-20 | 2004-08-26 | The Procter & Gamble Company | Phenethylamino sulfamic acids |
FR2851563B1 (fr) | 2003-02-26 | 2005-04-22 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
US20040224992A1 (en) | 2003-02-27 | 2004-11-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
EP1460069A1 (en) | 2003-03-20 | 2004-09-22 | MyoContract Ltd. | Substituted cyclohexyl and piperidinyl derivatives as melanocortin-4 receptor modulators |
CL2004000553A1 (es) | 2003-03-20 | 2005-02-04 | Actelion Pharmaceuticals Ltd | Uso de compuestos derivados de guanidina como antagonistas del receptor de neuropeptido ff; compuestos derivados de guanidina; procedimientos de preparacion; y composicion farmaceutica que los comprende. |
EP1468999A1 (en) | 2003-03-20 | 2004-10-20 | MyoContract Ltd. | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
DE602004021786D1 (de) | 2003-03-26 | 2009-08-13 | Actelion Pharmaceuticals Ltd | Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten |
FR2852957B1 (fr) | 2003-03-31 | 2005-06-10 | Sod Conseils Rech Applic | Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament |
JP2006522109A (ja) | 2003-03-31 | 2006-09-28 | 大正製薬株式会社 | 新規なキナゾリン誘導体及びそれらの使用に関連する治療方法 |
JP2004315511A (ja) | 2003-03-31 | 2004-11-11 | Taisho Pharmaceut Co Ltd | Mch受容体アンタゴニスト |
US20040199842A1 (en) | 2003-04-04 | 2004-10-07 | Sartschev Ronald A. | Test system with high accuracy time measurement system |
US20070027073A1 (en) | 2003-04-08 | 2007-02-01 | Menachem Rubinstein | Long-acting derivatives of pyy agonists |
MXPA05010945A (es) | 2003-04-09 | 2005-11-25 | Japan Tobacco Inc | Compuesto pentaciclico heteroaromatico y uso medicinal del mismo. |
GB0308335D0 (en) | 2003-04-10 | 2003-05-14 | Novartis Ag | Organic compounds |
WO2004089415A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
BRPI0409447A (pt) | 2003-04-14 | 2006-04-18 | Inst For Pharm Discovery Inc | ácidos fenilalcanóicos substituìdos |
CA2522225A1 (en) | 2003-04-17 | 2004-10-28 | Pfizer Products Inc. | Carboxamide derivatives as anti-diabetic agents |
EP1633709A1 (en) | 2003-04-30 | 2006-03-15 | Pfizer Products Inc. | Anti-diabetic agents |
ATE453620T1 (de) | 2003-05-01 | 2010-01-15 | Vernalis Res Ltd | Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten |
AU2003902260A0 (en) | 2003-05-09 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
WO2004108674A1 (ja) | 2003-06-05 | 2004-12-16 | Kissei Pharmaceutical Co., Ltd. | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
AU2003902828A0 (en) | 2003-06-05 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
BRPI0411131A (pt) | 2003-06-11 | 2006-07-18 | Merck & Co Inc | composto, método de tratar uma doença mediada pelo receptor de canabinóide 1, método de previnir a obesidade de uma pessoa com risco de obesidade, composição, e, uso de um composto |
WO2004111004A1 (en) | 2003-06-12 | 2004-12-23 | Novo Nordisk A/S | Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase |
US20060135523A1 (en) | 2003-06-18 | 2006-06-22 | Astrazeneca Ab | 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator |
GB0314057D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314049D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314261D0 (en) | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
MXPA05013951A (es) | 2003-06-19 | 2006-02-24 | Lilly Co Eli | Agonsita del receptor de la melanocortina 4 (mc4) y sus usos. |
KR100809201B1 (ko) | 2003-06-20 | 2008-02-29 | 에프. 호프만-라 로슈 아게 | 카나바노이드 수용체 1 역작용제로서 2-아미노벤조티아졸 |
US7355049B2 (en) | 2003-06-24 | 2008-04-08 | Hoffmann-La Roche Inc. | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator |
GB0314967D0 (en) | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
KR20060018902A (ko) | 2003-06-27 | 2006-03-02 | 텔 아비브 유니버시티 퓨쳐 테크놀로지 디벨롭먼트 엘.피. | 글리코겐 신타제 키나제-3 억제제 |
CA2530081A1 (en) | 2003-07-01 | 2005-01-13 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
AU2004259741A1 (en) | 2003-07-21 | 2005-02-03 | Smithkline Beecham Corporation | (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof |
JP2005042839A (ja) | 2003-07-23 | 2005-02-17 | Iseki & Co Ltd | 作業車両の変速制御装置 |
SI1648922T1 (sl) | 2003-07-31 | 2011-03-31 | Tranzyme Pharma Inc | Prostorsko opredeljene makrocikliäśne spojine uporabne za odkrivanje zdravil |
GB0318464D0 (en) | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
GB0318463D0 (en) | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
BRPI0413500A (pt) | 2003-08-12 | 2006-10-10 | Hoffmann La Roche | compostos, processos para a sua preparação, composição farmacêutica que compreende os mesmos, utilização de um composto, métodos para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade |
US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
US20050148643A1 (en) | 2003-08-19 | 2005-07-07 | Agouron Pharmaceuticals, Inc. | Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme |
WO2005019168A2 (en) | 2003-08-20 | 2005-03-03 | Pfizer Products Inc. | Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors |
KR20060120601A (ko) | 2003-08-22 | 2006-11-27 | 데이진 화-마 가부시키가이샤 | 키마제 저해제를 유효 성분으로서 함유하는 약제 |
TWI290140B (en) | 2003-08-25 | 2007-11-21 | Schering Corp | 2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for thr treatment of obesity and related disorders |
TW200519116A (en) | 2003-08-26 | 2005-06-16 | Teijin Pharma Ltd | Pyrrolopyrimidine derivatives |
WO2005023762A1 (en) | 2003-09-04 | 2005-03-17 | Abbott Laboratories | Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
WO2005051890A1 (en) | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
JP4922615B2 (ja) | 2003-11-26 | 2012-04-25 | 武田薬品工業株式会社 | 受容体機能調節剤 |
TW200522944A (en) | 2003-12-23 | 2005-07-16 | Lilly Co Eli | CB1 modulator compounds |
RU2006126978A (ru) | 2003-12-25 | 2008-01-27 | Такеда Фармасьютикал Компани Лимитед (Jp) | Производные 3-(4-бензилоксифенил)пропановой кислоты |
EP1698624B1 (en) | 2003-12-26 | 2012-06-27 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
NZ549046A (en) | 2004-02-13 | 2010-06-25 | Banyu Pharma Co Ltd | Fused-ring 4-oxopyrimidine derivative |
EP1737809B1 (en) | 2004-02-27 | 2013-09-18 | Amgen, Inc | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
CA2560111A1 (en) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
US7517910B2 (en) | 2004-03-30 | 2009-04-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
US20080021069A1 (en) | 2004-10-08 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Receptor Function Regulating Agent |
EP1843766A1 (en) | 2005-01-28 | 2007-10-17 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
ATE440091T1 (de) | 2005-01-31 | 2009-09-15 | Merck & Co Inc | Antidiabetische bicyclische verbindungen |
WO2006094209A2 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N-benzimidazolylalkyl-substituted amide sirtuin modulators |
US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
AU2006291234A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
US8321889B2 (en) | 2006-03-08 | 2012-11-27 | Kamfu Wong | Method and system for personalized and localized TV ad delivery |
JP2009530281A (ja) | 2006-03-14 | 2009-08-27 | アムジエン・インコーポレーテツド | 代謝障害の治療に有用である二環式カルボン酸誘導体 |
TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
EP2021327B1 (en) | 2006-05-15 | 2012-04-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
PT2248812E (pt) | 2006-06-27 | 2014-03-12 | Takeda Pharmaceutical | Compostos cíclicos fundidos como moduladores do receptor gpr40 |
WO2008030618A1 (en) | 2006-09-07 | 2008-03-13 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
WO2008054674A2 (en) | 2006-10-31 | 2008-05-08 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
EP2079467B1 (en) | 2006-10-31 | 2015-11-18 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
TW200838526A (en) | 2006-12-01 | 2008-10-01 | Astellas Pharma Inc | Carboxylic acid derivatives |
JP2010524932A (ja) | 2007-04-16 | 2010-07-22 | アムジエン・インコーポレーテツド | 置換ビフェニルフェノキシ−、チオフェニル−及びアミノフェニルプロパン酸gpr40調節物質 |
EP2170883A1 (en) | 2007-06-28 | 2010-04-07 | Merck Frosst Canada Ltd. | Substituted fused pyrimidines as antagonists of gpr105 activity |
WO2009001836A1 (en) | 2007-06-28 | 2008-12-31 | Semiconductor Energy Laboratory Co., Ltd. | Manufacturing method of semiconductor device |
US10395288B2 (en) | 2007-07-03 | 2019-08-27 | Collabra Technology, Inc. | Methods and systems for a private market: facilitating connections between buyers and sellers or exchangers of products and services while maintaining privacy |
WO2009042053A2 (en) | 2007-09-21 | 2009-04-02 | Merck & Co., Inc. | Neuromedin u receptor agonists and uses thereof |
BRPI0818253A2 (pt) | 2007-10-10 | 2015-04-07 | Amgen Inc | Moduladores de gpr40 bifenil substituídos |
EP2215068B1 (en) * | 2007-10-29 | 2012-06-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
AU2009220163B2 (en) | 2008-03-06 | 2011-10-06 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
US8394969B2 (en) | 2008-09-26 | 2013-03-12 | Merck Sharp & Dohme Corp. | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
CA2739888C (en) | 2008-10-15 | 2013-11-19 | Amgen Inc. | Spirocyclic gpr40 modulators |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
MX2011004505A (es) | 2008-10-29 | 2011-05-31 | Merck Sharp & Dohme | Derivados novedosos de bencimidazol ciclico, utiles como agentes antidiabeticos. |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2749663A1 (en) | 2009-01-23 | 2010-07-29 | Hubert B. Josien | Pentafluorosulpholane-containing antidiabetic compounds |
JP2012515781A (ja) | 2009-01-23 | 2012-07-12 | シェーリング コーポレイション | 架橋および縮合複素環式抗糖尿病化合物 |
US20110312967A1 (en) | 2009-01-23 | 2011-12-22 | Schering Corporation | Bridged and fused antidiabetic compounds |
EP2393810A1 (en) | 2009-02-05 | 2011-12-14 | Schering Corporation | Phthalazine-containing antidiabetic compounds |
EP2440541A1 (en) | 2009-06-09 | 2012-04-18 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
MX2012007474A (es) | 2009-12-25 | 2012-08-01 | Mochida Pharm Co Ltd | Derivados de 3-hidroxi-5-arilisotiazol novedosos. |
CN101865413B (zh) | 2010-06-28 | 2012-08-01 | 李晓锋 | 模拟真火的电子发光装置及其模拟真火的方法 |
WO2014019186A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
-
2013
- 2013-07-31 JP JP2015525549A patent/JP2015525782A/ja not_active Withdrawn
- 2013-07-31 EP EP13750427.0A patent/EP2880028B1/en active Active
- 2013-07-31 BR BR112015002080A patent/BR112015002080A2/pt active Search and Examination
- 2013-07-31 RU RU2015106909A patent/RU2015106909A/ru not_active Application Discontinuation
- 2013-07-31 US US14/418,147 patent/US9527875B2/en active Active
- 2013-07-31 CA CA2880901A patent/CA2880901A1/en not_active Abandoned
- 2013-07-31 US US13/955,282 patent/US20140045746A1/en not_active Abandoned
- 2013-07-31 AU AU2013296470A patent/AU2013296470B2/en not_active Ceased
- 2013-07-31 WO PCT/US2013/052961 patent/WO2014022528A1/en active Application Filing
- 2013-07-31 KR KR20157002342A patent/KR20150036245A/ko not_active Application Discontinuation
- 2013-07-31 MX MX2015001500A patent/MX2015001500A/es unknown
- 2013-08-01 AR ARP130102739A patent/AR091962A1/es unknown
- 2013-08-02 TW TW102127863A patent/TW201408644A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2880028A1 (en) | 2015-06-10 |
EP2880028B1 (en) | 2020-09-30 |
KR20150036245A (ko) | 2015-04-07 |
CA2880901A1 (en) | 2014-02-06 |
MX2015001500A (es) | 2015-04-08 |
TW201408644A (zh) | 2014-03-01 |
US9527875B2 (en) | 2016-12-27 |
AU2013296470A1 (en) | 2015-02-05 |
BR112015002080A2 (pt) | 2017-07-04 |
US20140045746A1 (en) | 2014-02-13 |
AR091962A1 (es) | 2015-03-11 |
US20150191495A1 (en) | 2015-07-09 |
JP2015525782A (ja) | 2015-09-07 |
AU2013296470B2 (en) | 2016-03-17 |
WO2014022528A1 (en) | 2014-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2015106909A (ru) | Антидиабетические трициклические соединения | |
RU2016150413A (ru) | Противодиабетические трициклические соединения | |
RU2015140066A (ru) | Противодиабетические бициклические соединения | |
JP2015525782A5 (ru) | ||
JP2017516771A5 (ru) | ||
US11753366B2 (en) | Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors | |
US20170342020A1 (en) | Modulators of the eif2alpha pathway | |
Sabbatini et al. | GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers | |
de Gaetano et al. | Asymmetric synthesis and biological evaluation of imidazole-and oxazole-containing synthetic lipoxin A4 mimetics (sLXms) | |
EA201390840A1 (ru) | Полициклический lpaантагонист и его применение | |
WO2013082540A1 (en) | Compositions and methods of treating a proliferative disease with a quinazolinone derivative | |
Del Rio et al. | VCE‐004.3, a cannabidiol aminoquinone derivative, prevents bleomycin‐induced skin fibrosis and inflammation through PPARγ‐and CB2 receptor‐dependent pathways | |
JP2016516074A5 (ru) | ||
JP2016513128A5 (ru) | ||
US11891399B2 (en) | Inhibitors of cancer invasion, attachment, and/or metastasis | |
Yu et al. | Overexpression of Gremlin 1 by sonic hedgehog signaling promotes pancreatic cancer progression | |
ECSP21091203A (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa | |
AU2017286128A1 (en) | Compounds, compositions and methods for prevention and/or treatment of cancer | |
Martin et al. | The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma | |
Sato et al. | Therapeutic targets and early stage clinical trials for pulmonary fibrosis | |
JP2020502094A (ja) | 免疫応答を調節するためのオキサビシクロヘプタン | |
Iovino et al. | Activation of the zinc-sensing receptor GPR39 promotes T-cell reconstitution after hematopoietic cell transplant in mice | |
RU2019102757A (ru) | Производные этинила | |
WO2016047799A1 (ja) | 脂質異常症治療剤 | |
Berkhout et al. | Pharmacodynamics of ceftazidime and avibactam in a neutropenic mouse lung model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170110 |